Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
extended-release naltrexone
- Development stage
- Approved
- Lead developer
- Alkermes
- Modality
- Small Molecules
- Administration
- Intramuscular
01
Overview
Extended-release naltrexone is a long-acting formulation of the opioid antagonist naltrexone, administered as a monthly intramuscular injection. It is FDA-approved for the treatment of both opioid use disorder (OUD) and alcohol use disorder (AUD). The drug works by binding to and blocking mu-opioid receptors in the brain, thereby reducing cravings and preventing the euphoric and sedative effects of opioids and alcohol. Extended-release formulations were developed to address issues with patient noncompliance seen with daily oral dosing. The most widely used product is based on a polylactide glycolide (PLG) polymer microsphere delivery system that allows for sustained release over four weeks[1][2][3][5]. Extended-release naltrexone should only be initiated after patients are fully detoxified from opioids to avoid precipitated withdrawal[2][6]. It is not addictive, does not cause withdrawal symptoms upon discontinuation, and has no abuse potential[1].
- Brand names
- Vivitrol
- Other names
- extended-release injectable naltrexoneXR-naltrexoneXR-NTX
02
Targets
DOR (Opioid Receptor Delta 1)KOR (Kappa opioid receptor)MOR (Mu opioid receptor)
Beyond the preview
Go deeper on extended-release naltrexone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on extended-release naltrexone.